摘要
目的了解鼓室内注射地塞米松对难治性自身免疫性感音神经性聋的疗效。方法对已经确诊为自身免疫性感音神经性聋的病例32例,在全身应用大剂量糖皮质激素后,听力无明显改善的病例15例,药物减量后听力再次出现反复的病例17例,予鼓室内注射地塞米松约3mg,每日一次,注射7天后,复查听力,听力无好转,再注射7天,随诊6个月,并监测听力变化,比较注射前与注射后14天、3个月、6个月(500、1K、2K、4KHz)气导纯音听阈的平均阈值和听性脑干电反应的波V反应阈。结果 32例自身免疫性感音神经性聋患者,鼓室注射治疗前平均听阈为64.92±25.36dBHL,听性脑干电反应波V平均反应阈为69.88±18.27dBnHL。治疗结束后平均听阈为46.58±29.32dBHL,波V平均反应阈为51.36±20.12dBnHL,经配对t检验,差异有统计学意义(P<0.05)。结论鼓室内注射地塞米松治疗自身免疫性感音神经性聋安全、有效,可用于对自身免疫性感音神经性聋的辅助治疗。
Objective To investigate the effect of intratympanic dexamethasone injection on autotimmune sensorineu- ral heating loss which is difficult to treat. Method Intratympanic injection of dexamethasone （3 mg qd for 7 days） was admin- istered in 32 cases of autotimmune sensotineural hearing loss, of which 15 showed no significant heating improvement after systemic glucocortieoid treatment and 17 showed hearing declination after glucocorticoid taper. If no hearing improvement af- ter 7 days, the treatment was repeated for another 7 days. At 6 months follow-up, hearing and ABR results were recorded and compared to before the injection. Results Average hearing threshold and mean wave V threshold were 64.92±25.36 dB HL and 69.88± 18.27 dB nHL, respectively, before intratympanic in the 32 patients, and 46.58±29.32 dB HL and 51.36±20.12 dB nHL respectively after intratympanic injection （P〈0.05）. Conclusion Intratympanic injection of dexamethasone is a safe and effective adjuvant treatment in the management of autotimmune sensorineural hearing loss.
出处
《中华耳科学杂志》
CSCD
北大核心
2013年第2期259-262,共4页
Chinese Journal of Otology
